Allarity Therapeutics Inc Dossier
Financial Snapshot
Revenue, profitability, returns, debt, and capital allocation
Revenue $345KTTM through 30 Jun 2026
Net Income -$12.3MTTM through 30 Jun 2026
Free Cash Flow -$13.8MTTM through 30 Jun 2026
Margins
| Current | |
|---|---|
| Operating Margin | -3,940.6% |
| Net Margin | -3,575.1% |
Returns
-114.3%ROE
-61.5%ROA
Balance Sheet Health
Debt / Equity0.14x
Current Ratio2.13x
Net Debt-$13.3Mnet cash position
Cash & Equivalents$17M
Quality Metrics
Altman Z-Score-6.55
Piotroski F-Score1 / 9
FCF Margin-3,994.8%
Earnings-Beat Rate100.0%
Multi-Year Trend
RevenueFY2025: $320K
Diluted EPSFY2025: $-0.78
Dividend
No dividend
Capital Allocation
Capex Intensity20.9%
Segment Performance
| Segment | Revenue | YoY | Outlook |
|---|---|---|---|
| Allarity Medical Laboratory | $300K | View detailsExpected to continue supporting external biotech clients with DRP analysis and gene expression services. |
Filing Detail Members
This section is available to registered members. Create a free account or sign in to unlock the full breakdown.